Quantcast
Channel: Daily Bankrupt Company Updates | Bankrupt Company News
Viewing all articles
Browse latest Browse all 4593

Orexigen Bankruptcy KERP Filed

0
0

Orexigen Therapeutics filed with the U.S. Bankruptcy Court a motion for entry of an order (i) authorizing implementation of a key employee incentive plan (KEIP) and a key employee retention plan (KERP) and (ii) approving the terms of the Debtors KEIP and KERP.

The motion explains, “The KERP covers 66 non-insiders with target award amounts equal to three month’s base salary of each participant. The total cost of the program is $3,115,000….In comparing the KEIP against other bankruptcy companies, the target Operational Incentive payouts for the two Participating Finance Employees at a cost of $131,250 funding was significantly lower than the 25th percentile of the market target Operational Incentive costs of $1.3M. The Debtor’s Asset Sale Incentives with an aggregate cost of $1.5M at target funding (assuming $100 million asset sale value) falls between the 25th percentile ($1.05M) and the 50th percentile ($1.74M) of the market Asset Sale target aggregate costs. Based on the Debtor’s aggregate Operational Incentive target payouts falling below the 25th percentile of the market reference companies, and the Debtor’s aggregate Asset Sale target payouts falling between the 25th and 50th percentile of the market reference companies, the Debtor’s KEIP aggregate costs were found to be reasonable in comparison.”

The Court scheduled an April 11, 2018 hearing to consider the motion, with objections due by April 4, 2018.

Read more healthcare bankruptcy news.

The post Orexigen Bankruptcy KERP Filed appeared first on Daily Bankrupt Company Updates | Bankrupt Company News.


Viewing all articles
Browse latest Browse all 4593

Latest Images

Trending Articles





Latest Images